期刊文献+

女性乳腺浸润性导管癌组织USP18、USP20、USP25与临床病理特征和预后的关系研究

Study on the Relationship between USP18,USP20,USP25 and Clinicopathological Features and Prognosis in Female Breast Invasive Ductal Carcinoma
原文传递
导出
摘要 目的:探讨女性乳腺浸润性导管癌组织中泛素特异性蛋白酶18(USP18)、泛素特异性蛋白酶20(USP20)、泛素特异性蛋白酶25(USP25)的表达与临床病理特征和预后的关系。方法:选取2017年3月-2020年3月四川省妇幼保健院和雅安市人民医院收治的女性乳腺浸润性导管癌患者98例作为研究对象,采用免疫组织化学方法检测乳腺浸润性导管癌组织和癌旁组织USP18、USP20、USP25的表达情况,分析癌组织中USP18、USP20和USP25的表达与临床病理特征间的关系。多因素Logistic回归分析女性乳腺浸润性导管癌预后的独立危险因素。Kaplan-Meier生存曲线分析USP18、USP20、USP25阴性和阳性表达患者预后的差异。结果:乳腺浸润性导管癌组织中USP20、USP18、USP25阳性表达率较癌旁组织更高(P<0.05);乳腺浸润性导管癌组织中USP20的阳性表达与分化程度、TNM分期有关(P<0.05);USP18的阳性表达与TNM分期、淋巴结转移、分子亚型、分化程度有关(P<0.05);USP25的阳性表达与淋巴结转移及分化程度有关(P<0.05)。多因素Logistic回归分析显示淋巴结转移、TNM Ⅲ期、USP18阳性表达、USP20阳性表达、USP25阳性表达均是影响患者预后的独立危险因素(P<0.05)。Kaplan-Meier生存曲线发现USP18、USP20、USP25阳性表达患者的3年未复发生存率分别为59.65%、59.32%、58.62%,分别低于USP18、USP20、USP25阴性表达患者的82.05%、83.78%、84.21%。结论:USP18、USP20、USP25在女性乳腺浸润性导管癌中的表达情况与淋巴结转移、TNM分期、分化程度以及分子亚型密切相关。USP18、USP20、USP25阳性表达是影响患者预后的独立危险因素,且与患者3年未复发生存率有关。 Objective:To investigate the relationship between the expression of ubiquitin-specific protease 18(USP18),ubiquitin-specific protease 20(USP20),ubiquitin-specific protease 25(USP25)and clinicopathological features and prognosis in female breast invasive ductal carcinoma.Methods:98 female patients with breast invasive ductal carcinoma admitted to Sichuan Provincial Maternity and Child Health Care Hospital and Ya'an People's Hospital from March 2017 to March 2020 were selected as the research objects,the expression of USP18,USP20 and USP25 in breast invasive ductal carcinoma tissues and adjacent tissues was detected by immunohistochemical methods,and the relationship between the expression of USP18,USP20 and USP25 in cancer tissues and clinicopathological features was analyzed.The independent risk factors for the prognosis of female breast invasive ductal carcinoma were analyzed by multivariat Logistic regression.The difference in prognosis between patients with negative and positive expression of USP18,USP20 and USP25 were analyzed by Kaplan-Meier survival curve.Results:The positive expression rates of USP20,USP18 and USP25 in breast invasive ductal carcinoma tissues were higher than those in adjacent tissues(P<0.05).The positive expression of USP20 in breast invasive ductal carcinoma was related to the degree of differentiation and TNM stage(P<0.05).The positive expression of USP18 was correlated with TNM stage,lymph node metastasis,molecular subtype and differentiation degree(P<0.05).The positive expression of USP25 was related to lymph node metastasis and differentiation (P<0.05). Multivariate Logistic regression analysis showedthat lymph node metastasis, TNM stage III, positive expression of USP18, positive expression of USP20 and positive expression ofUSP25 were independent risk factors affecting the prognosis of patients (P<0.05). Kaplan-Meier survival curve showed that the 3-yearrecurrence-free survival rates of patients with positive expression of USP18, USP20 and USP25 were 59.65% , 59.32% and 58.62%respectively, which were lower than 82.05%, 83.78% and 84.21% of patients with negative expression of USP18, USP20 and USP25respectively. Conclusion: The expression of USP18, USP20, and USP25 in invasive ductal carcinoma of the female breast is closelyrelated to lymph node metastasis, TNM staging, differentiation degree, and molecular subtypes. Positive expression of USP18, USP20,and USP25 is an independent risk factor affecting patient prognosis and is associated with a 3-year recurrence free survival rate.
作者 赵颖洁 雷秀娟 袁业伟 张洁妤 高霞 莫云路 ZHAO Ying-jie;LEI Xiu-juan;YUAN Ye-wei;ZHANG Jie-yu;GAO Xia;MO Yun-lu(Department of Pathology,Sichuan Provincial Maternity and Child Health Care Hospital,Chengdu,Sichuan,610045,China;Department of Breast and Thyroid Surgery,Sichuan Provincial Maternity and Child Health Care Hospital,Chengdu,Sichuan,610045,China;Pathogenic Biology Teaching and Research Office,Fuzhou Medical College of Nanchang University,Fuzhou,Jiangxi,344000,China;Department of Pathology,Ya'an People's Hospital,Ya'an,Sichuan,625000,China)
出处 《现代生物医学进展》 CAS 2024年第15期2995-3000,共6页 Progress in Modern Biomedicine
基金 四川省妇幼保健协会妇幼医学科技创新课题(22FXZD03)。
关键词 乳腺浸润性导管癌 USP18 USP20 USP25 临床病理特征 预后 Breast invasive ductal carcinoma USP18 USP20 USP25 Clinicopathologic features Prognosis
  • 相关文献

参考文献11

二级参考文献61

共引文献975

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部